Investigation of Clinically Significant Molecular Aberrations in Patients with Prostate Cancer: Implications for Personalized Treatment, Prognosis and Genetic Testing.
BRCA2
TMPRSS2-ERG
genomics
molecular profiling
mutations
overall survival
prognostic
prostate cancer
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
23 Jul 2023
23 Jul 2023
Historique:
received:
12
06
2023
revised:
10
07
2023
accepted:
12
07
2023
medline:
31
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
The data on tumor molecular profiling of European patients with prostate cancer is limited. Our aim was to evaluate the prevalence and prognostic and predictive values of gene alterations in unselected patients with prostate cancer. The presence of gene alterations was assessed in patients with histologically confirmed prostate cancer using the ForeSENTIA
Identifiants
pubmed: 37511593
pii: ijms241411834
doi: 10.3390/ijms241411834
pmc: PMC10380890
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Pfizer
ID : NA
Organisme : Hellenic Society of Medical Oncology
ID : NA
Organisme : HeCOG
ID : TR_9/19
Références
JAMA Oncol. 2019 Apr 01;5(4):471-478
pubmed: 30589920
J Clin Oncol. 2013 May 10;31(14):1748-57
pubmed: 23569316
Mol Cancer Ther. 2020 Jun;19(6):1373-1382
pubmed: 32220973
Br J Cancer. 2022 Nov;127(9):1680-1690
pubmed: 35986085
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
J Clin Oncol. 2019 Feb 20;37(6):490-503
pubmed: 30625039
JCO Precis Oncol. 2022 Apr;6:e2100543
pubmed: 35507889
JCO Precis Oncol. 2022 May;6:e2200234
pubmed: 35666082
JCO Precis Oncol. 2020 Nov;4:882-897
pubmed: 35050761
Nucleic Acids Res. 2019 Jan 8;47(D1):D506-D515
pubmed: 30395287
Lancet Oncol. 2021 Sep;22(9):1250-1264
pubmed: 34388386
Genome Res. 2017 Dec;27(12):2050-2060
pubmed: 29097403
Eur J Cancer. 2021 Apr;147:74-83
pubmed: 33626496
J Mol Diagn. 2017 Jan;19(1):4-23
pubmed: 27993330
Front Oncol. 2022 Mar 23;12:855463
pubmed: 35402285
JCO Precis Oncol. 2022 Jul;6:e2200195
pubmed: 35820087
Nat Rev Urol. 2019 Nov;16(11):645-654
pubmed: 31591549
N Engl J Med. 2012 Jan 12;366(2):141-9
pubmed: 22236224
JAMA Oncol. 2019 Apr 01;5(4):523-528
pubmed: 30730552
Br J Cancer. 2006 Jan 30;94(2):318-22
pubmed: 16421597
Cancer Biol Ther. 2019;20(2):219-226
pubmed: 30339521
Urol Oncol. 2022 Dec;40(12):538.e15-538.e24
pubmed: 36041976
Genome Biol. 2014 Jun 26;15(6):R84
pubmed: 24970577
Lancet Oncol. 2018 Jul;19(7):975-986
pubmed: 29880291
Cancer Cell. 2018 Mar 12;33(3):450-462.e10
pubmed: 29533785
N Engl J Med. 2023 Feb 23;388(8):719-732
pubmed: 36795891
Cold Spring Harb Perspect Biol. 2010 Jan;2(1):a001008
pubmed: 20182602
Br J Cancer. 2014 Sep 9;111(6):1238-40
pubmed: 25101567
Genome Med. 2018 Mar 28;10(1):25
pubmed: 29592813
Genome Res. 2018 Apr;28(4):581-591
pubmed: 29535149
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
Br J Cancer. 2008 Jul 22;99(2):371-4
pubmed: 18577985
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
N Engl J Med. 2015 Oct 29;373(18):1697-708
pubmed: 26510020
JCO Precis Oncol. 2022 Apr;6:e2100461
pubmed: 35476551
J Clin Oncol. 2020 Nov 10;38(32):3763-3772
pubmed: 32795228
Nucleic Acids Res. 2016 Jun 20;44(11):e108
pubmed: 27060149
Bioinformatics. 2019 Jun 1;35(11):1978-1980
pubmed: 30376034
N Engl J Med. 2016 Aug 4;375(5):443-53
pubmed: 27433846